Airsonett_Air4_news_page_low@1x

Thank you for showing an interest in Airsonett.

 

We help people with allergic diseases to improve their health-related quality of life, by developing and marketing our unique Temperature Laminar Airflow (TLA) technology.

For all press inquiries, please contact: press@airsonett.eu.

To find out more about studies and research on treatment with Air4 by Airsonett, click here.

New study evaluates Airsonett TLA technology in the treatment of children with severe atopic eczema

New study evaluates Airsonett TLA technology in the treatment of children with severe atopic eczema

November 9, 2020

Airsonett announced today that the company’s novel and proprietary technology TLA (Temperature-controlled Laminar Airflow) would be evaluated in the treatment of children with severe atopic eczema. Imperial College London UK will perform and sponsor the single centre, randomized placebo-controlled study. The study is a result of the positive results already seen in the proof of... Read More...

Information for our clients and patients with severe, uncontrolled allergic asthma in regards to the Corona virus

March 20, 2020

Airsonett have received queries about how we, as a company, work to minimise the spreading of the Corona virus and how we secure delivery of new Airsonett devices and filters to our clients and patients. We daily monitor the guidelines and directives from the UK Authorities and try to plan and act in a responsible... Read More...
New agreement for Airsonett with the region of Halland in Sweden for treatment of severe, uncontrolled allergic asthma and difficult-to-treat atopic eczema with TLA via public healthcare

New agreement for Airsonett with the region of Halland in Sweden for treatment of severe, uncontrolled allergic asthma and difficult-to-treat atopic eczema with TLA via public healthcare

March 19, 2020

Airsonett AB announced today that the company had signed an agreement with the region of Halland in Sweden. The agreement is for the treatment of patients with severe, uncontrolled allergic asthma and difficult-to-treat atopic eczema with the company’s patented technology Temperature-controlled Laminar Airflow (TLA). The technology gives patients particle- and allergen-free air when they rest... Read More...
Airsonett signs agreement with the region of Kalmar in Sweden for treatment of severe allergic asthma with TLA via public healthcare

Airsonett signs agreement with the region of Kalmar in Sweden for treatment of severe allergic asthma with TLA via public healthcare

November 20, 2019

Airsonett announced today that the company has signed an agreement with the region of Kalmar for the treatment of patients with severe allergic asthma. The agreement is the third of its kind for Airsonett in Sweden this year, for prescription of the company’s unique treatment; Temperature controlled Laminar Airflow (TLA). The technology treats severe allergic... Read More...
Patient survey: 97% have a better quality of life with Airsonett  

Patient survey: 97% have a better quality of life with Airsonett  

November 15, 2019

This year we have conducted an examination among users of Airsonett Air4 in Sweden with allergic asthma, and we are quite proud of the answers. A majority of the users answered, of which 97% (!) state that they have a better quality of life with the treatment. A majority of the users say that have... Read More...
Airsonett signs a new agreement: patients with severe allergic asthma in Region Västra Götaland can now receive treatment with TLA via public healthcare

Airsonett signs a new agreement: patients with severe allergic asthma in Region Västra Götaland can now receive treatment with TLA via public healthcare

September 20, 2019

Region Västra Götaland is the latest in a line of Swedish regions to sign an agreement with Air-sonett for TLA treatment. The regions Stockholm and Östergötland have previously signed similar agreements. The agreement is for prescription of the company’s unique treatment, Temperature controlled Laminar Airflow (TLA), that treats severe allergic asthma patients with particle-free air.... Read More...
The Swedish national healthcare region of Östergötland signs central agreement with Airsonett for treatment with TLA for patients with severe allergic asthma

The Swedish national healthcare region of Östergötland signs central agreement with Airsonett for treatment with TLA for patients with severe allergic asthma

July 8, 2019

The expert group for respiratory organs in the region of Östergötland has since 2016 recommended TLA as a complementary treatment for adults and children over 6 with severe asthma, who, despite optimal medication, have uncontrolled asthma. However, the prescription was previously limited to the allergy center in Linköping. With the new central agreement, it is... Read More...

Airsonett supports the Allergy Diary App – assists in the care of allergic asthma

March 1, 2019

The new app Allergy Diary has been developed for IOS and Android in collaboration between MACVIA-LR and ARIAR, a European network for monitoring allergy. The app is an important tool for the effective treatment of severe allergic asthma as it assists patients in keeping track of their symptoms. The app is simple to use, and... Read More...
Airsonett’s TLA technology is now included in the guidelines for treatment of severe asthma in the South Swedish national health care

Airsonett’s TLA technology is now included in the guidelines for treatment of severe asthma in the South Swedish national health care

January 22, 2019

National health care in the South Swedish region of Skåne has updated its guidelines for treatment of patients with severe allergic asthma. Airsonett and the treatment with the TLA technology (Temperature-controlled Laminar Airflow)has been given its own guidelines based on the primary indication to prevent asthma attacks (exacerbations). The guidelines have been established by the... Read More...

Airsonett Air4 provides a clinical improvement in Quality of Life within 3 months of treatment

January 11, 2019

An independent time to onset (TTO) study, using the Airsonett Air4 Temperature-controlled Laminar Airflow technology (TLA), by Professor Leif Bjermer (Department of Respiratory and Allergology, University Hospital Lund, Sweden), concludes that Nocturnal treatment with TLA provided a statistically significant and clinically relevant improvement in total Quality of Life score (AQLQ) within 3 months in patients... Read More...

Airsonett AIR4 maintains good control of severe allergic asthma after withdrawal of omalizumab

July 11, 2018

An independent study by Professor C. Wang concludes in the title of the study “A nocturnal temperature controlled laminar flow device (TLA) maintains good control of severe allergic asthma(SAA) after withdrawal of Omalizumab therapy”. The study will be published in a poster session at ERS on Asthma Management session on Sunday 16 September 2018. “We... Read More...

Airsonett AB announces that the company has appointed Anders Due-Boje as its new CEO

July 4, 2018

Airsonett AB is a medical device company with a unique technology developed to treat patients with severe asthma. The company is active in Europe, the US and recently signed a major co-operation agreement with a Chinese distributor. The company’s product Airsonett AIR-4 is a clinically validated, non-pharmaceutical treatment of asthma, which reduces allergens and other... Read More...

Airsonett recently signed agreement with distributor in Germany

April 26, 2018

“Germany is one of our key markets so we are pleased to have signed a distribution agreement with the medical device company OxyCare GmbH. The company is dedicated to promote and launch Airsonett AIR4 on the German market. OxyCare will not only market AIR4 but also handling all logistics,installations and training for the German market.... Read More...

New eczema study with Airsonett AIR4 published

March 13, 2018

Promising results from an independent prospective pilot study lead by Dr. Claudia Gore, Imperial College, London has recently been published. The study showed that treatment with Temperature controlled Laminar Airflow (TLA; Airsonett AIR4) can lead to a significant clinical improvement in children and adolescents with severe allergic eczema, with accompanying reduction in medication usage. Allergic... Read More...

Treatment with Airsonett AIR4 has sustained benefit in children and adolescents with severe allergic eczema (atopic dermatitis)

June 21, 2017

Promising results from an independent prospective pilot study lead by Dr. Claudia Gore, Imperial College, London, was presented Tuesday afternoon at the ongoing EAACI congress in Helsinki. The study showed that treatment with Temperature controlled Laminar Airflow (TLA; Airsonett) can lead to a significant clinical improvement in children and adolescents with severe allergic eczema, with... Read More...

Airsonett AIR4 can generate significant cost savings while still maintaining asthma-related quality of life according to an independent expert review

February 22, 2017

An independent expert review authored by John O Warner, Professor of Paediatrics, Imperial College London, was today published on-line in Therapeutic Advances in Respiratory Disease. The review concludes that temperature-controlled laminar airflow (TLA) treatment (Airsonett AIR4) improves asthma-related quality of life, reduces airway inflammation and the frequency of severe asthma exacerbations in patients with severe... Read More...

Airsonett increases its focus on global commercial expansion

November 23, 2016

Airsonett AB is expanding its International Sales Organization to increase the rate of its commercial expansion by recruiting a new VP Sales and Marketing and appointing a VP Distributor Sales and Business Development. Recently a number of independent expert groups, both in Sweden and the UK, have published positive evaluations of the company’s innovative home... Read More...

Professor Karl-Christian Bergmann, Charité – Berlin, presented Airsonett data at Allergo 2016 in Cologne

April 12, 2016

At Allergo-Update’s annual meeting in Cologne, Prof Karl-Christian Bergmann, Charité – Universitätsmedizin, Berlin, presented the latest Airsonett data as part of his speech on Aerobiology. Professor Bergmann pointed out that according to a recent publications, Airsonett treatment (TLA) decreases the number of emergency emissions and exacerbations for patients with severe allergic asthma. Moreover, for patients... Read More...

Airsonett AIR4 a cost-effective, drug-free alternative for patients with severe allergic asthma

March 23, 2016

An economic analysis, published today in published in BMJ Open Respiratory Research finds Airsonett AIR4 to be a cost-effective addition to treatment options in patients with uncontrolled severe allergic asthma. For high-risk individuals with more severe and less well controlled asthma the use of Airsonett AIR4 to reduce incidence of hospitalisation would be a cost... Read More...